Lexaria Bioscience: Drug Delivery Technology
Quickly and effective drug delivery technology
Lexaria Bioscience Corp. began developing its DehydraTECH™ technology in 2014. They’ve since strengthened and broadened the technology to an unprecedented degree. Lexaria is a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs.
Lexaria has also demonstrated early-stage effectiveness in improving delivery through human skin for the potential development of topically-administered products, including patches, creams and lotions.
Lexaria’s technology is currently being evaluated for improved delivery characteristics of antiviral drugs in the global fight against COVID-19.
Further, Lexaria operates four subsidiary companies to focus on its different commercial opportunities in their respective industries: Lexaria Pharma Corp. investigating new products for hypertension, anti-viral treatments and other drug classes; Lexaria Nicotine Corp. (16.67% owned by Altria Ventures Inc) investigating oral non-combusted tobacco-derived nicotine product formats; Lexaria Hemp Corp. pursuing business-to-business opportunities with cannabinoids such as cannabidiol from hemp; and Lexaria Canpharm Corp. operating a state-of-the-art Health Canada licensed laboratory capable of developing novel psychotropic cannabinoid formulations for potential commercialization in that sector where federally legal to do so. The Lexaria companies sub-license the company’s DehydraTECH technology worldwide for the delivery of fat-soluble active molecules and drugs.
For more information on Lexaria Bioscience Corp. (CSE: LXX, NASDAQ: LEXX) please click on the request investor info button.